An Qing Shi

Researchers are evaluating the safety and effectiveness of TQB3909 tablets in patients who have recurrent or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). This phase Ib/II clinical trial focuses on patients diagnosed according to specific criteria and aims to understand how well this treatment works and how safe it is for this population. The study investigates TQB3909, a drug designed to inhibit the B-cell lymphoma-2 (BCL-2) protein. Participants will receive TQB3909 tablets as part of the treatment regimen. The trial includes monitoring for side effects and disease response over time. The study will measure the recommended phase II dose and assess remission rates through evaluations conducted up to 34 months. Participants will be involved in assessments that include monitoring for adverse events, serious adverse events, and abnormal laboratory results. These will be tracked for up to 34 months to evaluate safety and treatment impact. The study also includes imaging tests for measurable lesions and pregnancy testing for women of childbearing potential. Overall, the trial may last up to nearly three years, with ongoing safety and effectiveness evaluations throughout.

Researchers are establishing a standardized clinical information database for liver cancer patients through a collaborative effort led by the Department of Hepatobiliary Surgery at the First Affiliated Hospital of the University of Science and Technology of China (USTC). This database aims to support high-quality real-world clinical studies and research on hepatocellular carcinoma and related liver cancers. Participants may receive routine treatments such as surgical operations including resection, ablation, transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC). They might also be treated with various anti-tumor drugs including immunologic, targeted, and chemotherapy medications. Treatments and clinical data are collected to enrich the database for future research. During the study, participants will provide blood samples and postoperative pathology residual samples and will be followed over time to monitor their health and treatment outcomes. The primary outcome measured is overall survival over 10 years. Participants must be willing to comply with follow-up visits and provide informed consent, ensuring comprehensive data collection for long-term analysis.

Researchers are evaluating the effectiveness and safety of oliceridine compared to morphine and sufentanil for managing pain after lumbar spine surgery. This randomized control trial involves 90 patients aged 18 to 65 years with physical health status classified as American Society of Anesthesiologists (ASA) grades I through III. The study aims to explore how well these drugs control postoperative pain and their safety profiles. Participants are randomly divided into three groups of 30 each. One group receives an initial intravenous dose of 1.5 mg oliceridine, followed ten minutes later by a continuous intravenous infusion at 0.01 mg per kilogram per hour mixed in saline at a rate of 2 ml per hour. The second group receives 4 mg of morphine intravenously, then a continuous infusion of morphine at 0.03 mg per kilogram per hour with saline at 2 ml per hour. The third group receives a 4 microgram loading dose of sufentanil intravenously, followed by continuous infusion at 0.03 micrograms per kilogram per hour in saline at 2 ml per hour. During the 48 hours following surgery, patients' pain levels are assessed using the Visual Analog Scale (VAS) both at rest and during exercise at six time points: 30 minutes, 2 hours, 6 hours, 12 hours, 24 hours, and 48 hours. Researchers also monitor any adverse reactions within the 48-hour postoperative period to evaluate safety. This detailed monitoring helps compare the pain relief and side effects of the three treatments over time.

Researchers are studying how deep neuromuscular block (NMB) affects recovery quality after laparoscopic hysterectomy in women. This study compares deep NMB combined with low-pressure pneumoperitoneum to moderate NMB with standard-pressure pneumoperitoneum. The goal is to understand if deep NMB can improve recovery and reduce pain after surgery. Participants are randomly assigned to one of two groups. Group A receives low-pressure pneumoperitoneum set at 8-10 mmHg with deep NMB, while Group B receives standard-pressure pneumoperitoneum set at 12-14 mmHg with moderate NMB. Both treatments are given during the laparoscopic hysterectomy procedure. During the study, researchers assess recovery quality one day after surgery using the Quality of Recovery-15 (QoR-15) questionnaire. They also monitor postoperative pain levels, surgical conditions, shoulder pain incidence, use of rescue pain medications, total analgesic doses, time to first bowel movement, nausea and vomiting, and time to removal of the breathing tube. These measures help evaluate the safety and effectiveness of the treatments.

Researchers are comparing different sizes of tracheal catheters to see which causes less sore throat in women after thyroid surgery. The study involves female patients aged 18 to 65 years who have an American Society of Anesthesiologists (ASA) physical status between I and III and are scheduled for elective thyroid surgery under general anesthesia. The goal is to evaluate the incidence and severity of sore throat following the use of smaller diameter catheters compared to the traditional 7.0 mm catheter. Participants are randomly divided into three groups, each receiving a different tracheal catheter size: 6.0 mm, 6.5 mm, or 7.0 mm inner diameter. All women undergo thyroid surgery with general anesthesia, and the study compares these three catheter sizes to determine their impact on postoperative sore throat. Women in the study will be monitored for sore throat at 1, 6, 24, and 48 hours after surgery. Researchers will record the occurrence and severity of sore throat at these times to understand differences between catheter sizes. The study includes careful follow-up to assess patient outcomes during this period.

This research aims to study the effects of vitamin D3 supplementation on cardiometabolic risk in Chinese adolescents who are overweight or obese and have vitamin D deficiency. The trial investigates whether taking vitamin D3 can improve cardiovascular metabolic health in this group. A total of 130 participants will be recruited from two middle schools and randomly assigned to different treatment groups. Participants in the intervention group will receive vitamin D3 supplements starting with a daily dose of 2000 IU for 6 weeks (taken as two capsules of 800 IU plus one capsule of 400 IU), followed by 800 IU per day for the next 6 weeks (one capsule). The control group will receive a placebo matching the supplement schedule: three capsules daily for the first 6 weeks and one capsule daily for the next 6 weeks. Supplement or placebo will be administered every two weeks during the first 6 weeks and every three weeks during the following 6 weeks. During the 12-week intervention, researchers will monitor participants' cardiometabolic risk factors by comparing changes from the start to the end of the study. Assessments will include blood tests for vitamin D levels and metabolic health markers. The main outcome measured is the change in cardiometabolic risk scores from baseline to post-intervention at 3 months. Safety and adherence will also be monitored throughout the study.

Researchers are evaluating the effectiveness and safety of two different durations of S-1 chemotherapy as adjuvant treatment after D2 surgery in patients with stage II gastric cancer. The study compares S-1 given for 9 months versus 1 year to see if the shorter treatment is not less effective than the longer one in improving disease-free survival and overall survival. This phase 3 trial aims to provide new insights into the optimal length of chemotherapy for these patients based on prior evidence showing S-1's benefit after D2 dissection in East Asian populations. Participants who have had a D2 resection for stage II gastric cancer are randomly assigned to receive S-1 chemotherapy either for 9 months or for 1 year. Both groups take S-1 in 3-week cycles, consisting of two weeks of daily doses (80-120 mg per day) followed by one week of rest. The study includes planned interim analyses to monitor safety and progress. Treatment is delivered orally and participants are followed for five years after their last enrollment to assess long-term outcomes. During the study, participants undergo regular evaluations including monitoring for side effects, disease recurrence, and survival status. The main measure of success is disease-free survival at 3 years, with overall survival at 5 years and safety also tracked. The study expects to ensure high quality through independent data monitoring committees and interim reviews. Total participant involvement lasts for several years, including treatment and follow-up periods to fully assess the impact of the chemotherapy duration.

Researchers are evaluating the safety and effectiveness of atorvastatin in adults aged 18 to 80 years who have experienced spontaneous intracerebral hemorrhage (ICH). This multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study plans to enroll 264 patients who arrive within 3 to 24 hours after symptom onset. The goal is to see if atorvastatin can improve recovery compared to standard medical treatment alone. Participants will be randomly assigned to one of two groups: one group will receive best medical treatment according to current ICH guidelines, and the other will receive the same treatment plus atorvastatin at a dose of 20 mg once daily for 21 days. Treatment is started within 48 hours of symptom onset or last known well time. The study focuses on patients with hematomas in the supratentorial brain region, with specific volume and coma scale criteria. During the study, participants will be monitored for functional outcomes, with the primary measure being the proportion of patients who have poor functional recovery at about 90 days, defined by a modified Rankin Scale score of 4 to 6. The study includes assessments through imaging to confirm diagnosis and careful tracking of symptoms and clinical status throughout the treatment and follow-up periods to evaluate safety and efficacy.

Researchers are studying how the combination of dexmedetomidine and esketamine affects sleep quality after modified radical mastectomy in women. The study focuses on whether using both drugs together improves sleep better than dexmedetomidine alone. This research involves women aged 25 to 65 years who are scheduled for this type of breast surgery and have good physical health status according to the American Society of Anesthesiologists. Participants are divided into three groups. One group receives dexmedetomidine alone before and during surgery. The second group receives dexmedetomidine plus a low dose of esketamine, and the third group receives dexmedetomidine plus a higher dose of esketamine. The drugs are given as infusions starting before anesthesia induction and continuing until shortly before surgery ends. During the study, researchers measure sleep quality the day after surgery using the Pittsburgh Sleep Quality Index. They also monitor vital signs like blood pressure and heart rate, pain levels, side effects including nausea, vomiting, hallucinations, agitation, and drowsiness, as well as recovery and extubation times. The study aims to see how these treatments impact sleep and recovery following surgery.

Researchers are investigating the prevalence, disease burden, and prognosis of chronic obstructive pulmonary disease (COPD) in patients aged 40 years or older with three types of cardiovascular diseases (CVD): coronary heart disease (CHD), atrial fibrillation (AF), and chronic heart failure (CHF). This multi-center, prospective, and interventional study aims to describe how common COPD is among these CVD patients and to observe how combined cardiopulmonary management affects their short-term prognosis. The study plans to enroll approximately 3,000 subjects, divided evenly among the three disease cohorts. The study involves a guideline education and implementation intervention delivered at both the investigator and patient levels. Investigators will receive education about COPD and CVD about four weeks before enrolling subjects. After enrollment, cardiologists and pulmonologists will provide patients with disease education every four weeks and collaborate on treatment management. Participants will be followed up every four weeks throughout the study period to monitor their health and treatment progress. Participants will undergo assessments including spirometry testing and questionnaires evaluated by investigators to confirm cognitive ability. Researchers will measure the number and percentage of COPD cases among subjects with CVD at baseline. Follow-up visits every four weeks will support ongoing treatment management and monitoring. The study duration and detailed timelines align with the intervention and follow-up schedules, ensuring comprehensive observation of patient outcomes and safety.